Benralizumab noninferior to mepolizumab for EGPA

Sarah Onuora

DOI: https://doi.org/10.1038/s41584-024-01116-6

IF: 32.286

2024-04-10

Nature Reviews Rheumatology

Abstract:In a head-to-head phase III trial of two drugs that target IL-5 or its receptor, benralizumab was noninferior to mepolizumab for the induction of remission in patients with eosinophilic granulomatosis with polyangiitis.

rheumatology

What problem does this paper attempt to address?

Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis

Michael E Wechsler,Parameswaran Nair,Benjamin Terrier,Bastian Walz,Arnaud Bourdin,David R W Jayne,David J Jackson,Florence Roufosse,Lena Börjesson Sjö,Ying Fan,Maria Jison,Christopher McCrae,Sofia Necander,Anat Shavit,Claire Walton,Peter A Merkel,Michael E. Wechsler,David R.W. Jayne,David J. Jackson,Peter A. Merkel

DOI: https://doi.org/10.1056/nejmoa2311155

IF: 158.5

2024-02-23

New England Journal of Medicine

Abstract:BACKGROUND: Eosinophilic granulomatosis with polyangiitis (EGPA) is a vasculitis characterized by eosinophilic inflammation. Benralizumab, a monoclonal antibody against the interleukin-5α receptor expressed on eosinophils, may be an option for treating EGPA.METHODS: We conducted a multicenter, double-blind, phase 3, randomized, active-controlled noninferiority trial to evaluate the efficacy and safety of benralizumab as compared with mepolizumab. Adults with relapsing or refractory EGPA who were receiving standard care were randomly assigned in a 1:1 ratio to receive benralizumab (30 mg) or mepolizumab (300 mg) subcutaneously every 4 weeks for 52 weeks. The primary end point was remission at weeks 36 and 48 (prespecified noninferiority margin, -25 percentage points). Secondary end points included the accrued duration of remission, time to first relapse, oral glucocorticoid use, eosinophil count, and safety.RESULTS: A total of 140 patients underwent randomization (70 assigned to each group). The adjusted percentage of patients with remission at weeks 36 and 48 was 59% in the benralizumab group and 56% in the mepolizumab group (difference, 3 percentage points; 95% confidence interval [CI], -13 to 18; P = 0.73 for superiority), showing noninferiority but not superiority of benralizumab to mepolizumab. The accrued duration of remission and the time to first relapse were similar in the two groups. Complete withdrawal of oral glucocorticoids during weeks 48 through 52 was achieved in 41% of the patients who received benralizumab and 26% of those who received mepolizumab. The mean (±SD) blood eosinophil count at baseline was 306.0±225.0 per microliter in the benralizumab group and 384.9±563.6 per microliter in the mepolizumab group, decreasing to 32.4±40.8 and 71.8±54.4 per microliter, respectively, at week 52. Adverse events were reported in 90% of the patients in the benralizumab group and 96% of those in the mepolizumab group; serious adverse events were reported in 6% and 13%, respectively.CONCLUSIONS: Benralizumab was noninferior to mepolizumab for the induction of remission in patients with relapsing or refractory EGPA. (Funded by AstraZeneca; MANDARA ClinicalTrials.gov number, NCT04157348.).

medicine, general & internal
Asthma remission in patients with eosinophilic granulomatosis with polyangiitis (EGPA) following treatment with benralizumab or mepolizumab

Bourdin,A.,Wechsler,M. E.,Jackson,D. J.,Siddiqui,S.,Baudy,P.,Menzies-Gow,A.,Necander,S.,Shavit,A.,Walton,C.

DOI: https://doi.org/10.1183/13993003.congress-2024.pa5364

IF: 24.3

2024-11-01

European Respiratory Journal

Abstract:Introduction: EGPA is an inflammatory disorder featuring asthma, eosinophilia, and vasculitis. This exploratory post-hoc analysis assessed whether patients with EGPA from the MANDARA study can achieve asthma remission. Methods: MANDARA was a Phase 3, randomised, 52-week double-blind study (NCT04157348) of benralizumab 1x30 mg (n=70) vs mepolizumab 3x100 mg (n=70) SC Q4W in patients with EGPA. All patients had asthma, eosinophilia and oral glucocorticoid (OGC) dose ≥7.5 mg/day ± immunosuppressants. Asthma remission (3-component) was defined as no asthma relapse during the 52-week period, OGC=0 mg/day and an Asthma Control Questionnaire (ACQ-6) score of –10%). Results: Patients had a mean (SD) age of 52.3 (14.1) years and 60.0% were women. The adjusted 3-component asthma remission rate was 33.6% and 22.3% for the benralizumab and mepolizumab groups respectively (difference: 11.25%; 95% CI: –3.19, 25.70; p=0.127; Figure). More benralizumab- than mepolizumab-treated patients achieved the 4-component remission (28.0% vs 12.4%; difference: 15.64%; 95% CI: 2.96, 28.32; p=0.016). Conclusion: Asthma remission is achievable in patients with EGPA after treatment with benralizumab or mepolizumab.

respiratory system
Late Breaking Abstract - Benralizumab reduces eosinophils and ANCA in sputum in EGPA

Mukherjee,M.,Suray Tan,N.,Huang,C.,Kim,B.,Radford,K.,Venegas Garrido,C.,Bhalla,A.,Rodriguez-Suarez,E.,Wechsler,M.,Walker,B.,Börjesson Sjö,L.,Necander,S.,Ashkar,A.,Weidner,J.,Sehmi,R.,Mccrae,C.,Khalidi,N.,Nair,P.

DOI: https://doi.org/10.1183/13993003.congress-2024.pa5372

IF: 24.3

2024-11-01

European Respiratory Journal

Abstract:Introduction: Benralizumab (30mg subcutaneous Q4W) is noninferior to mepolizumab (300mg sc Q4W) to induce clinical remission in patients with refractory EGPA (PMID: 38393328). Aims: We evaluated if treatment arms were associated with eosinophil reduction and ANCA in sputum in the randomized, double-blind, head-to-head MANDARA trial (NCT04157348). Methods: In a mechanistic sub-study (n=16) of the MANDARA trial, n=7 patients received benralizumab (52±11years, 57% female) and, n=9 received mepolizumab (58±16years, 78% female). Eosinophils, eosinophil activity (eosinophil peroxidase, EPX), T1/T2 cytokines and ANCA were assessed in blood and sputum pre- and post-treatment (PMID: 30179583). Results: Benralizumab reduced sputum eosinophils to <2.3% in 6/7 (86%) patients compared to mepolizumab (6/9, 66%) (2, P<0.01), but did not significantly reduce sputum EPX. At baseline, spANCA in both arms were comparable (mepo:4/9, 44%; benra: 3/7, 43%; only one sero-positive). Post-treatment, benralizumab significantly reduced spANCA levels compared to mepolizumab (P<0.05), with 2/7 (28%) remaining spANCA + . By comparison, there was an increase in the proportion of patients with spANCA on mepolizumab from baseline (6/9, 67%). Increase in spANCA correlated with spEPX (rho=0.65; P=0.01). The two patients on benralizumab who remained spANCA + had elevated spEPX and ACQ-6≥1.5 at the time-point of sampling, despite having achieved clinical remission. Reduction of T2 cytokines was comparable in both arms. However, an increase in spIL-17A post-mepolizumab (P<0.05) was noted that correlated with an increase in spANCA. Conclusions: Benralizumab has a greater effect on reducing sputum eosinophils and ANCA levels in EGPA compared to mepolizumab.

respiratory system
Efficacy and Safety of Benralizumab for Eosinophilic Asthma: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Bao-ping Tian,Gen-sheng Zhang,Jian Lou,Hong-bin Zhou,Wei Cui

DOI: https://doi.org/10.1080/02770903.2017.1379534

2017-01-01

Abstract:Context: Benralizumab is a humanized monoclonal antibody that targets the alpha chain of the IL-5 receptor (IL-5R alpha) and is currently being assessed in clinical trials for asthma control. Objective: Our systematic review and meta-analysis intends to evaluate the therapeutic efficacy and safety of benralizumab in patients with eosinophilic asthma. Data sources and extraction: Literature searches of PubMed, Embase, and the Cochrane Library were performed to identify randomized controlled trials of benralizumab and clinic outcomes in asthmatics. Results: In total, 7 articles with 2,321 subjects met our inclusion criteria. From this pooled analysis, we found that benralizumab significantly reduces exacerbations (RR: 0.63, 95% CI: 0.52-0.76, p < 0.00001; l(2) = 52%, p = 0.06) compared to placebo in eosinophilic asthma. There was no statistical trend for improvement in forced expiratory volume in 1 second or asthma control indices such as Quality of Life Assessment (AQLQ) and Asthma Control Questionnaire score in benralizumab-treated patients. In addition, safety data indicated that benralizumab administration resulted no increasing incidence of adverse events and was well tolerated (RR: 1.00, 95% CI: 0.95-1.05, p = 0.96; l(2) = 40%, p = 0.13). Conclusion: These results demonstrate the efficacy and safety of benralizumab for asthma patients with severe or uncontrolled symptoms and elevated eosinophils and provide support for benralizumab as an ideal option to treat asthma in this patient population.
Benralizumab for eosinophilic granulomatosis with polyangiitis

Adrien Cottu,Matthieu Groh,Charlene Desaintjean,Sylvain Marchand-Adam,Loïc Guillevin,Xavier Puechal,Stacy Beaumesnil,Estibaliz Lazaro,Maxime Samson,Camille Taille,Cécile-Audrey Durel,Elizabeth Diot,Sarah Nicolas,Laurent Guilleminault,Mikael Ebbo,Pascal Cathebras,Clairelyne Dupin,Halil Yildiz,Nabil Belfeki,Grégory Pugnet,Pierre Chauvin,Stephane Jouneau,Francois Lifermann,Jean-Philippe Martellosio,Vincent Cottin,Benjamin Terrier,French Vasculitis Study Group

DOI: https://doi.org/10.1136/ard-2023-224624

Abstract:Background: Benralizumab is effective in the treatment of eosinophilic asthma and is being investigated for the treatment of other eosinophil-associated diseases. Reports on the use of benralizumab for the treatment of eosinophilic granulomatosis with polyangiitis (EGPA) are limited to case reports and small case series. Methods: We conducted a multicentre, retrospective study including EGPA patients treated with off-label benralizumab. The primary endpoint was the rate of complete response defined as no disease activity (Birmingham Vasculitis Activity Score=0) and a prednisone dose ≤4 mg/day. Partial response was defined as no disease activity and a prednisone dose ≥4 mg/day. Results: Sixty-eight patients were included, including 31 (46%) who had previously received mepolizumab. The use of benralizumab was warranted by uncontrolled asthma in 54 (81%), persistent ear, nose and throat (ENT) manifestations in 27 (40%) and persistent glucocorticoids (GCs) use in 48 (74%) patients. Median (IQR) follow-up after starting benralizumab was 23 (9-34) months. Thirty-three patients (49%) achieved a complete response, 24 (36%) achieved a partial response and 10 (15%) did not respond. Among the 57 patients who initially responded, 10 (18%) eventually required further line treatments. GCs were discontinued in 23 patients (38%). Prior mepolizumab use was associated with a higher rate of primary failure (26.7% vs 5.4%, p=0.034) and less frequent GCs discontinuation (14.8% vs 55.9%, p=0.001). Vasculitis flares occurred in 7 patients (11%) and were associated with histological evidence of vasculitis and/or antineutrophil cytoplasmic antibodies positivity at benralizumab initiation (p=0.004). Conclusions: Benralizumab appears to be an effective treatment for refractory asthma or ENT manifestations in EGPA and allows GC-sparing. However, its efficacy was lower after prior failure of mepolizumab.
Benralizumab for eosinophilic granulomatosis with polyangiitis: a retrospective, multicentre, cohort study

Alessandra Bettiol,Maria Letizia Urban,Roberto Padoan,Matthieu Groh,Giuseppe Lopalco,Allyson Egan,Vincent Cottin,Paolo Fraticelli,Claudia Crimi,Stefano Del Giacco,Laura Losappio,Laura Moi,Francesco Cinetto,Marco Caminati,Pavel Novikov,Alvise Berti,Paolo Cameli,Pascal Cathébras,Angelo Coppola,Cécile-Audrey Durel,Marco Folci,Alberto Lo Gullo,Carlo Lombardi,Sara Monti,Paola Parronchi,Carlos Martinez Rivera,Roser Solans,Angelo Vacca,Georgina Espígol-Frigolé,Gabriella Guarnieri,Fulvia Chieco Bianchi,Maria Rita Marchi,Colas Tcherakian,Jean-Emmanuel Kahn,Florenzo Iannone,Vincenzo Venerito,Charlene Desaintjean,Gianluca Moroncini,Santi Nolasco,Giulia Anna Maria Luigia Costanzo,Jan Walter Schroeder,Camillo Ribi,Michelangelo Tesi,Elena Gelain,Irene Mattioli,Federica Bello,David Jayne,Domenico Prisco,Augusto Vaglio,Giacomo Emmi,European EGPA Study Group

DOI: https://doi.org/10.1016/S2665-9913(23)00243-6

Abstract:Background: Interleukin-5 (IL-5) inhibitors represent novel therapies for eosinophilic granulomatosis with polyangiitis (EGPA). This study assessed the effectiveness and safety of the IL-5 receptor inhibitor benralizumab in a European cohort of patients with EGPA. Methods: This retrospective cohort study included patients with EGPA from 28 European referral centres of the European EGPA Study Group across six countries (Italy, France, UK, Russia, Spain, and Switzerland) who received benralizumab as any line of treatment between Jan 1, 2019, and Sep 30, 2022. We assessed the rates of complete response, defined as no disease activity (Birmingham Vasculitis Activity Score [BVAS] of 0) and a prednisone dose of up to 4 mg/day, in contrast to partial response, defined as a BVAS of 0 and a prednisone dose greater than 4 mg/day. Active disease manifestations, pulmonary function, variation in glucocorticoid dose, and safety outcomes were also assessed over a 12-month follow-up. Findings: 121 patients with relapsing-refractory EGPA treated with benralizumab at the dose approved for eosinophilic asthma were included (64 [53%] women and 57 [47%] men; median age at the time of beginning benralizumab treatment 54·1 years [IQR 44·2-62·2]). Complete response was reported in 15 (12·4%, 95% CI 7·1-19·6) of 121 patients at month 3, 25 (28·7%, 19·5-39·4) of 87 patients at month 6, and 32 (46·4%, 34·3-58·8) of 69 patients at month 12; partial response was observed in an additional 43 (35·5%, 27·0-44·8) patients at month 3, 23 (26·4%, 17·6-37·0) at month 6, and 13 (18·8%, 10·4-30·1) at month 12. BVAS dropped from 3·0 (IQR 2·0-8·0) at baseline to 0·0 (0·0-2·0) at months 3 and 6, and to 0·0 (0·0-1·0) at month 12. The proportion of patients with systemic manifestations, active peripheral neurological disease, ear, nose, and throat involvement, and pulmonary involvement decreased, with an improvement in lung function tests. Six patients relapsed after having a complete response. The oral prednisone (or equivalent) dose decreased from 10·0 mg/day (5·0-12·5) at baseline to 5·0 mg/day (3·6-8·5) at month 3 (p<0·01), to 5·0 mg/day (2·5-6·3) at month 6, and to 2·5 mg/day (0·0-5·0) at month 12 (p<0·0001). 19 (16%) of 121 patients had adverse events and 16 (13%) discontinued benralizumab. Interpretation: These data suggest that benralizumab could be an effective treatment for EGPA in real-life clinical practice. Further clinical trials are required to confirm the efficacy of benralizumab in patients with a higher baseline disease activity. Funding: None.
Mepolizumab and benralizumab in patients with severe asthma and a history of eosinophilic granulomatosis with polyangiitis

Charlene Desaintjean,Kaïs Ahmad,Julie Traclet,Mathieu Gerfaud-Valentin,Cecile-Audrey Durel,Jean-Charles Glerant,Arnaud Hot,François Lestelle,Sabine Mainbourg,Mouhamad Nasser,Pascal Seve,Ségolène Turquier,Gilles Devouassoux,Vincent Cottin

DOI: https://doi.org/10.3389/fmed.2024.1341310

IF: 3.9

2024-03-22

Frontiers in Medicine

Abstract:Introduction Asthma associated with eosinophilic granulomatosis with polyangiitis (EGPA) is often severe and corticosteroid-dependent, leading to significant morbidity. Mepolizumab and benralizumab are humanized monoclonal antibodies targeting interleukin 5 (IL-5) and its receptor, respectively. They have been shown to be effective in steroid-sparing in patients with severe eosinophilic asthma. Objective Our aim was to evaluate the efficacy and safety of mepolizumab and benralizumab prescribed for severe asthma in patients with EGPA under “real-world” conditions. Methods This was a retrospective analysis of patients with EGPA and persistent asthma who received either mepolizumab 100 or 300 mg administered every 4 weeks, or benralizumab 30 mg administered every 4 weeks for the initial 3 injections and followed by an injection every 8 weeks thereafter, whilst combined with oral glucocorticoids. The follow-up every 6 ± 3 months included an assessment of clinical manifestations, pulmonary function tests and eosinophil cell count. The primary outcome was the proportion of patients at 12 months receiving a daily oral dose of prednisone or equivalent of 4 mg or less with a BVAS of 0. Results Twenty-six patients were included. After 12 months of treatment with mepolizumab or benralizumab, 32% of patients met the primary outcome and were receiving less than 4 mg of prednisone per day with a BVAS of 0. The median dose of prednisone was 10 mg per day at baseline, 9 mg at 6 months, and 5 mg at 12 months ( p ≤ 0.01). At 12 months, 23% of patients were weaned off corticosteroids, while an increase or no change in dose was observed in 27% of patients. The median eosinophil count was significantly reduced from 365 cells/mm 3 to 55 cells/mm 3 at 6 months and 70 cells/mm 3 at 12 months, respectively. No significant change was observed in FEV1. After 12 months of treatment, 14% of patients had had an average of 1 exacerbation of asthma, compared with 52% of patients before baseline. The tolerability profile was favorable. Conclusion In this real-world study in patients with severe asthma and a history of EGPA asthma, mepolizumab and benralizumab had a significant steroid-sparing effect and reduced asthma exacerbation, but no significant effect on lung function.

medicine, general & internal
Efficacy and Safety of Benralizumab Compared with Mepolizumab in the Treatment of Eosinophilic Granulomatosis with Polyangiitis in Patients Receiving Standard of Care Therapy: Phase 3 MANDARA Study

Michael Wechsler,Parameswaran Nair,Benjamin Terrier,Bastian Walz,Arnaud Bourdin,David Jayne,David Jackson,Florence Roufosse,Lena Börjesson Sjö,Ying Fan,Maria Jison,Christopher McCrae,Sofia Necander,Anat Shavit,Claire Walton,Peter Merkel

DOI: https://doi.org/10.1016/j.jaci.2023.11.868

IF: 14.29

2024-02-07

Journal of Allergy and Clinical Immunology

Abstract:MANDARA compared efficacy and safety of benralizumab and mepolizumab in patients with eosinophilic granulomatosis with polyangiitis (EGPA) receiving standard of care.

immunology,allergy
Efficacy and safety of benralizumab in eosinophilic granulomatosis with polyangiitis: A meta‐analysis of eight studies

Federico Spataro,Antonio Giovanni Solimando,Attilio Di Girolamo,Angelo Vacca,Roberto Ria

DOI: https://doi.org/10.1111/eci.14333

2024-10-12

European Journal of Clinical Investigation

Abstract:This meta‐analysis of eight studies evaluates the efficacy and safety of benralizumab in patients with eosinophilic granulomatosis polyangiitis (EGPA). Findings demonstrate a significant reduction in oral corticosteroid (OCS) usage with a mean reduction of 8.25 mg/day, achieved remission in 56.8% of patients, and immunosuppressants withdrawal in 28.1%, over a mean follow‐up of about 1 year. Adverse events were mild, with only one discontinuation. Benralizumab is effective and well‐tolerated in managing EGPA. Objective Eosinophilic granulomatous polyangiitis (EGPA) is a rare autoimmune disease characterized by multisystemic inflammation, with eosinophils playing a central role in its pathogenesis. Traditional management relies heavily on corticosteroids and immunosuppressants, which are associated with significant side effects. The emergence of biologic agents, such as benralizumab, offers targeted therapeutic options by inhibiting the interleukin‐5 receptor α, thereby reducing eosinophilic inflammation. Methods This systematic review and meta‐analysis comprehensively evaluate the efficacy and safety of benralizumab in EGPA patients, focusing on its ability to reduce oral corticosteroid (OCS) use, facilitate remission and spare immunosuppressants. We searched MEDLINE, LILACS and ISI Web of Science databases for relevant studies up to July 2024. Results Eight studies, including both randomized controlled trials (RCTs) and observational studies, were included in the meta‐analysis, involving a total of 396 EGPA patients. The pooled analysis demonstrated a significant reduction in OCS dose, with an overall estimated effect of −8.25 mg/day (95% CI, −9.39 to −7.10). Complete remission was achieved in 56.8% of patients, and immunosuppressants were reduced or discontinued in 28.1% of cases. Adverse events (AEs) were reported in 21.9% of patients, with only one discontinuation due to an AE. Conclusion These findings provide robust evidence supporting the use of benralizumab as an effective and well‐tolerated treatment option for EGPA, significantly reducing OCS requirements and offering promising remission rates. Future research should focus on larger, multicentre RCTs to confirm these findings and further elucidate the long‐term benefits and safety profile of benralizumab in EGPA.

medicine, general & internal, research & experimental
Mepolizumab for Eosinophilic Granulomatosis With Polyangiitis: A European Multicenter Observational Study

Alessandra Bettiol,Maria Letizia Urban,Lorenzo Dagna,Vincent Cottin,Franco Franceschini,Stefano Del Giacco,Franco Schiavon,Thomas Neumann,Giuseppe Lopalco,Pavel Novikov,Chiara Baldini,Carlo Lombardi,Alvise Berti,Federico Alberici,Marco Folci,Simone Negrini,Renato Alberto Sinico,Luca Quartuccio,Claudio Lunardi,Paola Parronchi,Frank Moosig,Georgina Espígol‐Frigolé,Jan Schroeder,Anna Luise Kernder,Sara Monti,Ettore Silvagni,Claudia Crimi,Francesco Cinetto,Paolo Fraticelli,Dario Roccatello,Angelo Vacca,Aladdin J. Mohammad,Bernhard Hellmich,Maxime Samson,Elena Bargagli,Jan Willem Cohen Tervaert,Camillo Ribi,Davide Fiori,Federica Bello,Filippo Fagni,Luca Moroni,Giuseppe Alvise Ramirez,Mouhamad Nasser,Chiara Marvisi,Paola Toniati,Davide Firinu,Roberto Padoan,Allyson Egan,Benjamin Seeliger,Florenzo Iannone,Carlo Salvarani,David Jayne,Domenico Prisco,Augusto Vaglio,Giacomo Emmi,Kais Ahmad,Mirko Beccalli,Bernard Bonnotte,Roberto Bortolotti,Adriana Cariddi,Marco Caminati,Maria C Cid,Margherita Deidda,Paolo Delvino,Gerardo Di Scala,Mara Felicetti,Francesco Ferro,Federica Furini,Elena Gelain,Giulia Ghirelli,Julia Holle,Laura Michelina Losappio,Alfred Mahr,Danilo Malandrino,Juliane Marhhold,Irene Mattioli,Laura Moi,Sergey Moiseev,Francesco Muratore,Santi Nolasco,Bianca Olivieri,Adalgisa Palermo,Francesca Regola,Oliver Sander,Riccardo Scarpa,Savino Sciascia,Elena Silvestri,Nicola Susca,Benjamin Terrier,Elena Treppo,Barbara Trezzi,Martina Uzzo,Gianfranco Vitiello,Elaine Yacyshyn,,

DOI: https://doi.org/10.1002/art.41943

2021-12-30

Abstract:ObjectiveMepolizumab proved efficacious for eosinophilic granulomatosis with polyangiitis (EGPA, former Churg-Strauss) at the dosage of 300mg/4 weeks in the randomized controlled MIRRA trial. Few successful real-life experiences with the dosage approved for severe eosinophilic asthma (100mg/4 weeks) were recently reported. We retrospectively assessed the effectiveness and safety of mepolizumab 100 and 300mg/4 weeks in a large European EGPA cohort. MethodsWe included all EGPA patients treated with mepolizumab at the recruiting centres in 2015-2020. Treatment response was evaluated from month 3 through 24 (T3-T24) after mepolizumab starting. Complete response (CR) was defined as no disease activity (Birmingham Vasculitis Activity Score, BVAS=0) and a prednisone dose ≤4mg/day. Respiratory outcomes included asthma and ear-nose-throat (ENT) exacerbations. ResultsWe included 203 patients, of whom 191 at stable dosage (158 mepolizumab 100mg/4 weeks, 33 300mg/4 weeks). At T3, 25 patients (12.3%) had a CR. CR rates increased to 30.4% and 35.7% at T12 and T24 and were comparable between mepolizumab 100 and 300mg/4 weeks. Mepolizumab led to a significant reduction in BVAS, prednisone dose, eosinophil counts from T3 through T24, with no significant differences between 100 and 300 mg/4weeks. Eighty-two patients (40.4%) experienced asthma exacerbations [57/158 (36%) on 100mg/4 weeks; 17/33 (52%) on 300mg/4 weeks]. Thirty-one (15.3%) experienced ENT exacerbations. Forty-four patients (21.7%) experienced adverse events, most being non-serious (38/44). ConclusionMepolizumab both at 100 and 300mg/4 weeks is effective for EGPA. The two dosages should be compared in the setting of a controlled trial.

rheumatology
Benralizumab for eosinophilic gastritis: a single-site, randomised, double-blind, placebo-controlled, phase 2 trial

Kara L Kliewer,Cristin Murray-Petzold,Margaret H Collins,Juan P Abonia,Scott M Bolton,Lauren A DiTommaso,Lisa J Martin,Xue Zhang,Vincent A Mukkada,Philip E Putnam,Erinn S Kellner,Ashley L Devonshire,Justin T Schwartz,Vidhya A Kunnathur,Chen E Rosenberg,John L Lyles,Tetsuo Shoda,Amy D Klion,Marc E Rothenberg

DOI: https://doi.org/10.1016/S2468-1253(23)00145-0

Abstract:Background: In eosinophilic gastrointestinal diseases, the role of eosinophils in disease pathogenesis and the effect of eosinophil depletion on patient outcomes are unclear. Benralizumab, an eosinophil-depleting monoclonal antibody that targets the interleukin-5 receptor α, might eliminate gastric tissue eosinophils and improve outcomes in eosinophilic gastritis. We aimed to assess the efficacy and safety of benralizumab in patients with eosinophilic gastritis. Methods: We conducted a single-site, randomised, double-blind, placebo-controlled, phase 2 trial at Cincinnati Children's Hospital Medical Center (Cincinnati, OH, USA). Individuals aged 12-60 years with symptomatic, histologically active eosinophilic gastritis (peak gastric eosinophil count ≥30 eosinophils per high-power field [eos/hpf] in at least five hpfs) and blood eosinophilia (>500 eosinophils per μL [eos/μL]) were randomly assigned (1:1, block size of four) to benralizumab 30 mg or placebo, stratified by the use of glucocorticoids for gastric disease. Investigators, study staff, and study participants were masked to treatment assignment; statisticians were unmasked when analysing data. Treatments were administered subcutaneously once every 4 weeks for a 12-week double-blind period (three total injections). The primary endpoint was the proportion of patients who achieved histological remission (peak gastric eosinophil count <30 eos/hpf) at week 12. Key secondary endpoints were the changes from baseline to week 12 in peak gastric eosinophil count, blood eosinophil count, eosinophilic gastritis histology (total, inflammatory, and structural feature scores), Eosinophilic Gastritis Endoscopic Reference System (EG-REFS) score, and patient-reported outcome symptom measures (Severity of Dyspepsia Assessment [SODA] and Patient-Reported Outcome Measurement Information System [PROMIS] short-form questionnaire). After the 12-week double-blind period, patients were eligible for entry into two open-label extension (OLE) periods up to week 88, in which all patients received benralizumab. Efficacy was analysed in the intention-to-treat (ITT) population and safety was assessed in all patients who received at least one dose of study drug. The trial was registered on ClinicalTrials.gov, NCT03473977, and is completed. Findings: Between April 23, 2018, and Jan 13, 2020, 34 patients were screened, and 26 were subsequently randomly assigned to benralizumab (n=13) or placebo (n=13) and included in the ITT and safety populations (mean age 19·5 years [SD 7·3]; 19 [73%] male patients and seven [27%] female patients). At week 12, ten (77% [95% CI 50 to 92]) of 13 patients who received benralizumab and one (8% [1 to 33]) of 13 who received placebo achieved histological remission (difference 69 percentage points [95% CI 32 to 85]; p=0·0010). Changes from baseline to week 12 were significantly greater in the benralizumab group versus the placebo group for peak gastric eosinophil counts (mean -137 eos/hpf [95% CI -186 to -88] vs -38 eos/hpf [-94 to 18]; p=0·0080), eosinophilic gastritis histology total score (mean -0·31 [-0·42 to -0·20] vs -0·02 [-0·16 to 0·12]; p=0·0016), histology inflammatory score (mean -0·46 [-0·60 to -0·31] vs -0·04 [-0·22 to 0·13]; p=0·0006), and blood eosinophil counts (median -1060 eos/μL [IQR -1740 to -830] vs -160 eos/μL [-710 to 120]; p=0·0044). Changes were not significantly different between the groups for eosinophilic gastritis histology structural score (mean -0·07 [95% CI -0·19 to 0·05] vs 0·03 [-0·09 to 0·15]; p=0·23), EG-REFS score (mean -1·0 [-2·3 to 0·3] vs -0·5 [-2·0 to 1·0]; p=0·62), or in patient-reported outcomes (SODA and PROMIS). During the double-blind period, treatment-emergent adverse events occurred in 11 (85%) of 13 patients in the benralizumab group and six (46%) of 13 in the placebo group; the most common treatment-emergent adverse events were headache (six [46%] vs two [15%] patients), nausea (three [23%] vs two [15%]), and vomiting (two [15%] vs three [23%]). There were no treatment-related deaths. Two patients had serious adverse events (dizziness and rhabdomyolysis in one patient; aspiration in one patient) during the OLE periods, which were considered unrelated to study treatment. Interpretation: Benralizumab treatment induced histological remission, as defined by absence of tissue eosinophilia, in most patients with eosinophilic gastritis. However, the persistence of histological, endoscopic, and other features of the disease suggest a co-existing, eosinophil-independent pathogenic mechanism and the need for broader targeting of type 2 immunity. Funding: AstraZeneca and the Division of Intramural Research (National Institute of Allergy and Infectious Diseases, US National Institutes of Health).
Long-Term Effectiveness of Benralizumab in Eosinophilic Granulomatosis With Polyangiitis

Alexandra M Nanzer,Anne-Catherine Maynard-Paquette,Vardah Alam,Linda Green,Louise Thomson,Jodie Lam,Mariana Fernandes,Cris Roxas,Grainne d'Ancona,Andrew Hearn,Jessica Gates,Sangita Agarwal,Brian D Kent,Michelle Fernando,David P D'Cruz,Claire Hopkins,Tevfik F Ismail,Jaideep Dhariwal,David J Jackson,Alexandra M. Nanzer,Grainne d’Ancona,Brian D. Kent,David P. D’Cruz,Tevfik F. Ismail,David J. Jackson

DOI: https://doi.org/10.1016/j.jaip.2024.01.006

2024-01-01

Abstract:BACKGROUND: Eosinophilic granulomatosis with polyangiitis (EGPA) is a multisystemic disease characterized by eosinophilic tissue inflammation. Benralizumab, an anti-IL-5 receptor (anti-IL-5R) monoclonal antibody, induces rapid depletion of eosinophils; its longer-term effect in EGPA is unknown.OBJECTIVE: To assess the real-world effectiveness and clinical remission rates of anti-IL-5R therapy in EGPA.METHODS: We performed a retrospective cohort analysis of patients with EGPA, who commenced treatment with benralizumab. Clinical remission, assessed at 1 year and 2 years after the initiation of benralizumab, was defined as an absence of active vasculitis (Birmingham Vasculitis Activity Score of 0) and an oral corticosteroid (OCS) dose of ≤4 mg/d of prednisolone. "Super-responders" were defined as patients in remission and free of any significant relapses (asthma or extrapulmonary) over the preceding 12 months. The corticosteroid-sparing capacity of benralizumab, patient-reported outcome measures, and characteristics associated with clinical remission and super-responder status were also analyzed.RESULTS: A total of 70 patients completed at least 1 year of treatment with benralizumab, of whom 53 completed 2 years. Of 70 patients, 47 (67.1%) met the definition for clinical remission at 1 year, with a similar proportion in remission at 2 years. Excluding asthma-related relapses, 61 of 70 (87.1%) patients were relapse free at 1 year, and of the 53 who completed 2 years, 45 (84.9%) were relapse free. A total of 67.9% of patients no longer needed any OCS for disease control. No significant difference was seen between antineutrophilic cytoplasmic antibody (ANCA)-positive and ANCA-negative subgroups.CONCLUSIONS: In this real-world setting of patients with EGPA, treatment with benralizumab was well tolerated and resulted in corticosteroid-free clinical remission for the majority of patients.

immunology,allergy
Benralizumab Reduces Respiratory Exacerbations and Oral Glucocorticosteroid Dose in Patients with Severe Asthma and Eosinophilic Granulomatosis with Polyangiitis

DOI: https://doi.org/10.2147/jaa.s461800

2024-06-07

Journal of Asthma and Allergy

Abstract:Carlo Mümmler, 1 Pontus Mertsch, 1 Michaela Barnikel, 1 Frank Haubner, 2 Ulf Schönermarck, 3 Ulrich Grabmaier, 4 Hendrik Schulze-Koops, 5 Jürgen Behr, 1 Nikolaus Kneidinger, 1, 6 Katrin Milger 1 1 Department of Medicine V, LMU University Hospital, LMU Munich, Comprehensive Pneumology Center, Member of the German Center of Lung Research (DZL), Munich, Germany; 2 Department of Otorhinolaryngology, LMU University Hospital, LMU Munich, Munich, Germany; 3 Division of Nephrology, Department of Medicine IV, LMU University Hospital, LMU Munich, Munich, Germany; 4 Department of Medicine I, LMU University Hospital, LMU Munich, Munich, Germany; 5 Division of Rheumatology and Clinical Immunology, Department of Medicine IV, LMU University Hospital, LMU Munich, Munich, Germany; 6 Division of Pulmonology, Department of Internal Medicine, Medical University of Graz, Graz, Austria Correspondence: Katrin Milger, Department of Medicine V, LMU University Hospital, Marchioninistr, 15, LMU Munich, Munich, 81377, Germany, Tel +49-89-4400-73071, Email Background: Benralizumab reduces exacerbations and long-term oral glucocorticosteroid (OCS) exposure in patients with severe eosinophilic asthma. In patients with eosinophilic granulomatosis with polyangiitis (EGPA), uncontrolled symptoms and exacerbations of asthma and chronic rhinosinusitis (CRS) are important reasons for continued OCS therapies. We aimed to describe outcomes of patients with severe asthma and EGPA treated with benralizumab in real-life. Methods: We retrospectively analyzed adult patients from the Severe Asthma Unit at LMU Munich diagnosed with severe asthma and EGPA treated with benralizumab, differentiating two groups: Group A, patients with a stable daily OCS dose and diagnosis of EGPA > 6 months ago; and Group B, patients treated with high-dose daily OCS due to recent diagnosis of EGPA < 6 months ago. We compared outcome parameters at baseline and 12 months after initiation of benralizumab, including respiratory exacerbations, daily OCS dose, and lung function. Results: Group A included 17 patients, all receiving OCS therapy and additional immunosuppressants; 15 patients (88%) continued benralizumab for more than 12 months, demonstrating a significant reduction in daily OCS dose and exacerbations while FEV1 increased. Group B included 9 patients, all with high-dose daily OCS and some receiving cyclophosphamide pulse therapy for life-threatening disease. Benralizumab addition during induction was well tolerated. A total of 7/9 (78%) continued benralizumab for more than 12 months and preserved EGPA remission at the 12-month timepoint. Conclusion: In this real-life cohort of patients with severe asthma and EGPA, benralizumab initiation during remission maintenance reduced respiratory exacerbations and daily OCS dose. Benralizumab initiation during remission induction was associated with a high rate of clinical EGPA remission. Keywords: EGPA, asthma, CRS, vasculitis, glucocorticoid, OCS, anti-IL5R, biologics, benralizumab Eosinophilic granulomatosis with polyangiitis (EGPA), formerly known as Churg–Strauss syndrome, is a rare systemic vasculitis manifesting with a specific combination of clinical features. It occurs in patients with asthma and eosinophilia after a prodromal phase of varying length, with general symptoms like fever and weight loss marking the onset of systemic inflammatory disease. 1 EGPA mostly affects the respiratory tract with asthma and pulmonary infiltrates as well as upper airway disease, mostly chronic rhinosinusitis with nasal polyps (CRSwNP). Further, it can involve almost every organ, with cutaneous, cardiovascular, neurological, renal, or gastrointestinal manifestations being most frequent. 1,2 Antineutrophil cytoplasmic autoantibodies (ANCA) have been reported in approximately 40% of patients with EGPA in larger, rheumatologic cohorts, usually with specificity against myeloperoxidase (MPO-ANCA) or in rare cases cANCA, 3,4 but in recent trials lower proportions of ANCA-positivity have been observed. 5 EGPA is classified among the ANCA-associated vasculitis syndromes even though (MPO-) ANCA are often negative and vasculitis is not always detectable. 6 Histological characteristics are eosinophilic infiltration and inflammation, necrotizing vasculitis, and extravascular granuloma. 1 Oral glucocorticosteroids (OCS) are the mainstay of treatment in both the remission induction as well as the maintenance phase. 1,7 For remission induction, high-dose OCS and in case of organ- or life-threatening disease add-on cycloph -Abstract Truncated-

immunology,allergy,respiratory system
Sequential rituximab and mepolizumab in eosinophilic granulomatosis with polyangiitis (EGPA): a European multicentre observational study

Alessandra Bettiol,Maria Letizia Urban,Federica Bello,Davide Fiori,Irene Mattioli,Giuseppe Lopalco,Florenzo Iannone,Allyson Egan,Lorenzo Dagna,Marco Caminati,Simone Negrini,Elena Bargagli,Marco Folci,Franco Franceschini,Roberto Padoan,Oliver Flossmann,Roser Solans,Jan Schroeder,Marc André,Laura Moi,Paola Parronchi,Dario Roccatello,Savino Sciascia,David Jayne,Domenico Prisco,Augusto Vaglio,Giacomo Emmi

DOI: https://doi.org/10.1136/ard-2022-222776

IF: 27.973

2022-11-11

Annals of the Rheumatic Diseases

Abstract:Eosinophilic granulomatosis with polyangiitis (EGPA) is an anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis characterised by eosinophilic (eg, respiratory involvement, cardiomyopathy, gastroenteritis) and vasculitic manifestations (eg, neuropathy, glomerulonephritis).1 Rituximab is an established treatment in granulomatosis with polyangiitis and microscopic polyangiitis, and growing evidence indicates that it seems effective also in EGPA, mainly to induce and maintain remission of vasculitic involvement.2 3 However, its efficacy on respiratory manifestations seems limited. Conversely, the anti-IL5 mepolizumab, recently licensed for relapsing-refractory EGPA, is effective on respiratory manifestations, although it may also partially control systemic ones.3–5 Based on the idea that combining treatments with complementary mechanisms of action might induce and maintain remission of both disease components,6 7 we investigated the efficacy and safety of a regimen based on sequential rituximab and mepolizumab for the control of EGPA. This multicentre,...

rheumatology
Real-world mepolizumab treatment in eosinophilic granulomatosis with polyangiitis reduces disease burden in the United States

Sameer K. Mathur,Jared Silver,Sean D. MacKnight,Ana Urosevic,Cristina Martinez,Kaixin Zhang,François Laliberté,Arijita Deb

DOI: https://doi.org/10.1016/j.anai.2024.11.004

2024-11-20

Abstract:Background Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare, chronic inflammatory disease characterized by asthma and small/medium vessel vasculitis. Mepolizumab is approved for use in EGPA disease management alongside oral corticosteroids (OCS), but evidence of its real-world impact is limited. Objective To compare real-world treatment patterns and health outcomes, particularly OCS use, EGPA-related hospitalizations/relapses, and asthma exacerbations pre- and post-mepolizumab initiation in US patients with EGPA. Methods Patients with EGPA receiving ≥2 mepolizumab doses were identified using administrative claims data from Komodo Health's Comprehensive Dataset (December 2016–March 2020). Outcomes assessed pre- and post-mepolizumab initiation included corticosteroid/other medication use, EGPA-related hospitalizations/relapses, and asthma exacerbations. Results Overall, 114 patients were identified; of these, 60 (53%) received mepolizumab 300 mg at index. Average daily OCS dose per dispensing was significantly lower post- versus pre-mepolizumab initiation (21.2 vs 26.8 mg/day, 21% relative reduction, P<0.001); mean number of OCS bursts also decreased (0.9 vs 1.8, 50% relative reduction, P<0.001). Patients experienced significantly lower rates of EGPA-related hospitalization (0.86 vs 1.55 per person-year [PPY], 49% relative reduction, P=0.004) and EGPA relapse (3.18 vs 3.94 PPY, 19% relative reduction, P=0.004) post- versus pre-initiation. Most patients (91%) had an asthma diagnosis at baseline; among these patients, asthma exacerbation rates were significantly lower post- versus pre-initiation (1.05 vs 1.84 PPY, 42% relative reduction, P=0.004). Conclusion Mepolizumab was associated with significant steroid-sparing benefits and significantly reduced rates of EGPA-related hospitalizations, EGPA relapses, and asthma exacerbations in this real-world study of US patients with EGPA, confirming the benefits of mepolizumab treatment seen in clinical trials.

immunology,allergy
Real-world clinical remission of severe asthma with benralizumab in Spanish adults with severe asthma

Eva Martinez-Moragon,Eusebi Chiner,Alexandra Suliana Mogrovejo,Marta Palop Cervera,Inmaculada Lluch Tortajada,Ignacio Boira Enrique,Andrés Fernando Sánchez Vera

DOI: https://doi.org/10.1080/02770903.2024.2332351

2024-04-06

Journal of Asthma

Abstract:Objective Patients with severe eosinophilic asthma experience high risk of exacerbations and reduced quality of life. Benralizumab, a monoclonal antibody binding to IL-5 receptor α subunit, is an approved drug for its treatment. The objective was to describe clinical remission after benralizumab prescription in routine clinical practice.

allergy,respiratory system
Safety and effectiveness of mepolizumab therapy in remission induction therapy for eosinophilic granulomatosis with polyangiitis: a retrospective study

Masanobu Ueno,Ippei Miyagawa,Takafumi Aritomi,Koichi Kimura,Shigeru Iwata,Kentaro Hanami,Syunsuke Fukuyo,Satoshi Kubo,Yusuke Miyazaki,Shingo Nakayamada,Yoshiya Tanaka

DOI: https://doi.org/10.1186/s13075-022-02845-3

2022-06-29

Abstract:Objectives: To investigate the safety and effectiveness of mepolizumab (MPZ), an anti-interleukin-5 antibody, as remission induction therapy for severe eosinophilic granulomatosis with polyangiitis (EGPA). Methods: The clinical courses of patients with severe EGPA over 6 months were retrospectively investigated and compared between patients treated with high-dose corticosteroid (CS) plus MPZ therapy (MPZ group, n = 7) and those treated with high-dose CS plus intravenous cyclophosphamide (IVCY) pulse therapy (IVCY group, n = 13). The primary endpoints were the MPZ retention rate and the IVCY completion rate. The secondary endpoints were adverse events and changes in the Birmingham Vasculitis Activity Score (BVAS), Vascular Damage Index (VDI), eosinophil counts, and concomitant CS doses, and the extent and rates of these changes were compared between the MPZ and IVCY groups. Results: Regarding the primary endpoints, the MPZ retention rate was 100%, and the IVCY completion rate was 61.5%. Regarding the secondary endpoints, adverse events were detected in 2/7 patients (28.6%) in the MPZ group and 7/13 patients (53.8%) in the IVCY group. BVAS and eosinophil counts significantly decreased in both groups at and after month 1, but there was no significant difference in the magnitude of changes between the two groups. VDI scores did not significantly increase in either group, and the degree of changes did not significantly differ between the two groups. Although concomitant CS doses significantly decreased at and after month 1 in both groups, the rates of decrease in CS doses at and after month 3 were significantly higher in the MPZ group. Conclusions: This study suggested that the use of MPZ as remission induction therapy for severe EGPA might be safe and effective for controlling disease activity and reducing CS doses.
Mepolizumab exerts crucial effects on glucocorticoid discontinuation in patients with eosinophilic granulomatosis with polyangiitis: a retrospective study of 27 cases at a single center in Japan

Takashi Yamane,Akira Hashiramoto

DOI: https://doi.org/10.1186/s13075-023-03097-5

2023-06-26

Abstract:Objectives: To investigate the efficacy of mepolizumab in patients with eosinophilic granulomatosis with polyangiitis (EGPA) and factors contributing to glucocorticoid (GC) discontinuation. Methods: We retrospectively studied EGPA patients treated with mepolizumab who were on GC at the time of induction of mepolizumab, at Japanese single center as of January 2023. Patients were classified into those who were able to discontinue GC at the time of the investigation (GC-free group) and those who continued (GC-continue group). Patient characteristics at the time of EGPA diagnosis (age, gender, absolute eosinophil counts, serum CRP level, serum IgE level, Rheumatoid factor (RF) / anti-neutrophil cytoplasmic antibody (ANCA) positivity, presence of asthma, affected organ, Five factor score (FFS), Birmingham Vasculitis Activity Score (BVAS) and characteristics at the time of mepolizumab induction (daily prednisolone dose, concomitant immunosuppressive maintenance therapy at the mepolizumab induction, prior history of GC pulse therapy, concomitant immunosuppressive therapy for remission induction,), history of relapse before mepolizumab induction and the duration of mepolizumab treatment were compared. We also followed the clinical indicators (absolute eosinophil counts, CRP and IgE levels, BVAS, Vascular Damage Index (VDI)) and daily prednisolone dosage at the EGPA diagnosis, at the mepolizumab induction and at the survey. Results: Twenty-seven patients were included in the study. At the time of the study, patients had received mepolizumab for median 31 months (IQR, 26 to 40), the daily prednisolone dose was median 1 mg (IQR, 0 to 1.8) and GC-free was achieved in 13 patients (48%). Among clinical indicators that have improved by conventional therapy before the induction of mepolizumab, eosinophil counts, GC doses and BVAS have successively shown significant reductions throughout the observation period both GC-free and GC-continue. Of the GC-free patients, 7 were ANCA positive and 12 had FFS1 or more. Univariate analysis showed that the absolute eosinophil counts at diagnosis was significantly higher in the GC-free group (median 8165/µl (IQR, 5138 to 13,409) vs. 4360/µl (IQR, 151 to 8380), P = 0.037) and significantly fewer patients presented with gastrointestinal lesions (2 (15%) vs. 8 (57%), P = 0.025), while multivariate analysis showed no significant differences. Mepolizumab treatment significantly improved VDI in the GC-continue group (P = 0.004). Conclusions: After three years of treatment with mepolizumab, approximately 50% of patients with EGPA achieved GC-free status. GC could be discontinued even in severe cases and ANCA-positive cases. Although multivariate analysis did not extract any significant factors contributing to achieving GC-free, we found that improvement in eosinophil counts and BVAS led to GC reduction, resulted in protection of organ damages in both the GC-free and continuation groups. The significance of achieving GC-free remission in EGPA patients was demonstrated.
Long-Term Safety of Mepolizumab in EGPA: Results From the Long-Term Access Programme

Paneez Khoury,Jared Silver,Gerhard Wolff,Rejina Verghis,Michael Wechsler

DOI: https://doi.org/10.1016/j.jaci.2023.11.890

IF: 14.29

2024-02-07

Journal of Allergy and Clinical Immunology

Abstract:Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare, relapsing/remitting disease with heterogeneous manifestations. The Phase III MIRRA RCT demonstrated the safety and efficacy of anti-IL-5 therapy mepolizumab over 52 weeks, leading to approval for EGPA in adults. Data on the extended safety profile of mepolizumab in EGPA are limited. The Long-term Access Programme (LAP;MEA116841/NCT03298061) monitored the extended safety of real-word mepolizumab use in patients with EGPA.

immunology,allergy
Sustained remission induced by 2 years of treatment with benralizumab in patients with severe eosinophilic asthma and nasal polyposis

Corrado Pelaia,Claudia Crimi,Alida Benfante,Maria Filomena Caiaffa,Raffaele Campisi,Claudio Candia,Giovanna Elisiana Carpagnano,Isabella Carrieri,Maria D'Amato,Aikaterini Detoraki,Maria Pia Foschino Barbaro,Nicola Lombardo,Luigi Macchia,Angelantonio Maglio,Elena Minenna,Santi Nolasco,Giuseppe Paglino,Francesco Papia,Luisa Ricciardi,Nicola Scichilone,Giulia Scioscia,Giuseppe Spadaro,Pasquale Tondo,Simona Uletta Lionetti,Giuseppe Valenti,Alessandro Vatrella,Nunzio Crimi,Girolamo Pelaia

DOI: https://doi.org/10.1111/resp.14767

IF: 6.9

2024-06-08

Respirology

Abstract:This real‐life study recruited 164 patients with SEA. After 24 months of benralizumab treatment, 42.1% achieved sustained remission. During the same period, CRSwNP improvement was observed in 40.2% out of 82 subjects with concomitant nasal polyps. The latter comorbidity and reversibility of airflow limitation were independent predictors of sustained remission. Background and Objective Several randomized controlled trials (RCTs) have shown that benralizumab is characterized by a good profile of efficacy and safety, thereby being potentially able to elicit clinical remission on‐treatment of severe eosinophilic asthma (SEA). The main goal of this multicentre observational study was to verify the effectiveness of benralizumab in inducing a sustained remission on‐treatment of SEA in patients with or without comorbid chronic rhinosinusitis with nasal polyps (CRSwNP). Methods Throughout 2 years of treatment with benralizumab, a four‐component evaluation of sustained remission of SEA was performed, including the assessment of SEA exacerbations, use of oral corticosteroids (OCSs), symptom control and lung function. Results The present study recruited 164 patients suffering from SEA. After 24 months of add‐on biological therapy with benralizumab, 69 (42.1%) achieved the important target of sustained remission on‐treatment (exacerbation rate = 0, OCS dose = 0, pre‐bronchodilator FEV1 ≥80% pred., ACT score ≥ 20). During the same period, a persistent improvement of CRSwNP (SNOT‐22

respiratory system

Benralizumab noninferior to mepolizumab for EGPA

Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis

Asthma remission in patients with eosinophilic granulomatosis with polyangiitis (EGPA) following treatment with benralizumab or mepolizumab

Late Breaking Abstract - Benralizumab reduces eosinophils and ANCA in sputum in EGPA

Efficacy and Safety of Benralizumab for Eosinophilic Asthma: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Benralizumab for eosinophilic granulomatosis with polyangiitis

Benralizumab for eosinophilic granulomatosis with polyangiitis: a retrospective, multicentre, cohort study

Mepolizumab and benralizumab in patients with severe asthma and a history of eosinophilic granulomatosis with polyangiitis

Efficacy and Safety of Benralizumab Compared with Mepolizumab in the Treatment of Eosinophilic Granulomatosis with Polyangiitis in Patients Receiving Standard of Care Therapy: Phase 3 MANDARA Study

Efficacy and safety of benralizumab in eosinophilic granulomatosis with polyangiitis: A meta‐analysis of eight studies

Mepolizumab for Eosinophilic Granulomatosis With Polyangiitis: A European Multicenter Observational Study

Benralizumab for eosinophilic gastritis: a single-site, randomised, double-blind, placebo-controlled, phase 2 trial

Long-Term Effectiveness of Benralizumab in Eosinophilic Granulomatosis With Polyangiitis

Benralizumab Reduces Respiratory Exacerbations and Oral Glucocorticosteroid Dose in Patients with Severe Asthma and Eosinophilic Granulomatosis with Polyangiitis

Sequential rituximab and mepolizumab in eosinophilic granulomatosis with polyangiitis (EGPA): a European multicentre observational study

Real-world mepolizumab treatment in eosinophilic granulomatosis with polyangiitis reduces disease burden in the United States

Real-world clinical remission of severe asthma with benralizumab in Spanish adults with severe asthma

Safety and effectiveness of mepolizumab therapy in remission induction therapy for eosinophilic granulomatosis with polyangiitis: a retrospective study

Mepolizumab exerts crucial effects on glucocorticoid discontinuation in patients with eosinophilic granulomatosis with polyangiitis: a retrospective study of 27 cases at a single center in Japan

Long-Term Safety of Mepolizumab in EGPA: Results From the Long-Term Access Programme

Sustained remission induced by 2 years of treatment with benralizumab in patients with severe eosinophilic asthma and nasal polyposis